GlassScriptPhysician profile
Stephanie Humbert
NPI 1356022560
$3,068.16
in general payments reported to CMS, 2019-2025
16 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $293 · 2024: $1,766 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $563.17 | 2023-2025 | |
| Novo Nordisk INC | $562.06 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $417.47 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $392.38 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $242.51 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $225.17 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $195.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $103.60 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $99.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.77 | 2023-2025 | Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.06 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2023-2024 | Glassia |
| Idorsia Pharmaceuticals US INC | $34.88 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $22.63 | 2024 | Keveyis |
| Corcept Therapeutics | $16.81 | 2023 | Korlym |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.44 | 2023 | Vaxneuvance, Gardasil 9, Vaqta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Humbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.